Schechter, Meir
Melzer Cohen, Cheli
Fishkin, Alisa
Rozenberg, Aliza
Yanuv, Ilan
Sehtman-Shachar, Dvora R.
Chodick, Gabriel
Clark, Alice
Abrahamsen, Trine J.
Lawson, Jack
Karasik, Avraham
Mosenzon, Ofri
Funding for this research was provided by:
Novo Nordisk
Article History
Received: 25 February 2023
Accepted: 7 April 2023
First Online: 27 May 2023
Declarations
:
: The study was approved by the institutional review board (IRB) at MHS. Due to the de-identified nature of the data, the IRB did not require obtaining informed consent from the participants.
: Not applicable.
: MS reports travel support from Novo Nordisk and AstraZeneca through Haddasah Medical Center. CMC, AF, DRS, and GC have no conflict of interest to declare. IY and AR receive hourly payment from AstraZeneca through Hadassah Medical Center and from Novo Nordisk. AC and JL are employees of NovoNordisk. TJA is an employee and a shareholder of NovoNordisk. AK has received research grants and speaking honoraria from AstraZeneca, Novo Nordisk, and Boehringer Ingelheim. Starting May 1st 2023, I am an employee of Regeneron Pharmacutical. OM reports Advisory Board: Novo Nordisk, Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca, BOL Pharma. Research grant support through Hadassah Hebrew University Hospital: Novo Nordisk, AstraZeneca. Speaker's Bureau: AstraZeneca, Novo Nordisk, Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim.